Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30863576 | 1.00 | ALDH1A1 (0.43) | ALDH1A1TDP1POLBL3MBTL1IDO1 | |
| Water SCHEMBL27581485 | 0.97 | ALDH1A1 (0.41) | ALDH1A1TDP1POLBL3MBTL1IDO1 | |
| SCHEMBL29441997 | 0.78 | ALDH1A1 (0.52) | ALDH1A1TDP1POLBL3MBTL1IDO1 | |
| SCHEMBL63469 | 0.78 | ALDH1A1 (0.52) | ALDH1A1TDP1POLBL3MBTL1IDO1 | |
| SCHEMBL13601605 | 0.77 | MPL (0.40) | ALDH1A1TDP1POLBL3MBTL1IDO1 | |
| SCHEMBL13601607 | 0.77 | HSD11B1 (0.40) | ALDH1A1TDP1POLBL3MBTL1IDO1 | |
| Hydrogen Sulfide SCHEMBL28274662 | 0.76 | ALDH1A1 (0.50) | ALDH1A1TDP1POLBL3MBTL1IDO1 | |
| SCHEMBL23324839 | 0.75 | CA2 (0.39) | ALDH1A1TDP1POLBL3MBTL1LMNA | |
| SCHEMBL21303635 | 0.74 | ALDH1A1 (0.39) | ALDH1A1TDP1POLBL3MBTL1IDO1 | |
| SCHEMBL72183 | 0.74 | ALDH1A1 (0.44) | ALDH1A1TDP1POLBL3MBTL1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4705853-B2 | — | — | 2011-06-22 | — | — | JP | claimed |
| EP-1517928-A1 | SUPPORTED HYBRID METALLOCENE CATALYST, METHOD FOR PREPARING THE SAME, AND METHOD FOR PREPARING POLYOLEFIN USING THE SAME | LG Chem, LTD. LG Twin Tower (KR) | 2005-03-30 | — | — | EP | claimed |
| WO-2004087770-A1 | SUPPORTED HYBRID METALLOCENE CATALYST, METHOD FOR PREPARING THE SAME, AND METHOD FOR PREPARING POLYOLEFIN USING THE SAME | LG CHEM LTD. (KR) | 2004-10-14 | — | — | WO | claimed |
| US-11844276-B2 | Organic electroluminescent device emitting blue light | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-12-12 | — | — | US | disclosed |
| EP-3755695-B1 | ORGANIC MOLECULES, ESPECIALLY FOR USE IN OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO LTD (KR) | 2023-10-11 | — | — | EP | disclosed |
| US-11674163-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof | ARENA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230063469-A1 | Organic Electroluminescent Device Emitting Blue Light | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-03-02 | — | — | US | disclosed |
| US-11149292-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof | ARENA PHARMACEUTICALS, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-10807946-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200119286-A1 | ORGANIC ELECTROLUMINESCENT DEVICE EMITTING BLUE LIGHT | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-04-16 | — | — | US | disclosed |
| WO-2019162332-A1 | ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2019-08-29 | — | — | WO | disclosed |
| EP-1670768-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| CN-101184731-A | Indoline compounds | FOURNIER LAB SA (FR) | 2008-05-21 | — | — | CN | disclosed |
| WO-2007092435-A2 | 11-BETA HSD1 INHIBITORS | WYETH (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1517928-A1 | SUPPORTED HYBRID METALLOCENE CATALYST, METHOD FOR PREPARING THE SAME, AND METHOD FOR PREPARING POLYOLEFIN USING THE SAME | LG Chem, LTD. LG Twin Tower (KR) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004087770-A1 | SUPPORTED HYBRID METALLOCENE CATALYST, METHOD FOR PREPARING THE SAME, AND METHOD FOR PREPARING POLYOLEFIN USING THE SAME | LG CHEM LTD. (KR) | 2004-10-14 | — | — | WO | disclosed |
| CN-1447813-A | Late transition metal complexes, their use as catalysts and polymers therefrom | EXXONMOBIL RES & ENG CO (US) | 2003-10-08 | — | — | CN | disclosed |
| CN-1085218-C | Olefin polymerization catalyst | ASAHI CHEMICAL IND (JP) | 2002-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | S1PR1, S1PR2, S1PR4 | ALDH1A1 708/4885TDP1 598/4885POLB 4614/4885 |
| US-11674163-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof | S1PR1, S1PR5, S1PR2 | ALDH1A1 312/4885TDP1 2001/4885POLB 3601/4885 |
| US-10807946-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | ALDH1A1 4657/4885TDP1 4534/4885POLB 4495/4885 |
| US-11149292-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof | S1PR1, S1PR5, S1PR2 | ALDH1A1 312/4885TDP1 2001/4885POLB 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.